A Missed Boat on New River
When you pick stocks for a living, whether it's as a portfolio manager, trader, analyst or columnist, you're bound to end up with both winners and losers over time. Every so often, a stock will end up burned in your memory as an example of perfect execution or everything going wrong.
Over the past several months, I detailed the biotech company's sky-high valuation, its insider sales, its hiring of an executive that signaled expectations of a tough regulatory environment and most of all my belief that Vyvanse, its attention deficit hyperactivity disorder drug, will not be as successful as the Street expects.
But despite my being a nattering nabob of negativity, Shire found value to the tune of $2.6 billion in New River's business. Along with Vyvanse, Shire also obtains NRP290 -- a drug currently in phase II trials that is intended to be a safer and abuse-resistant alternative to acute pain medications such as Vicodin, OxyContin and Percocet -- and NRP409, a treatment for hypothyroidism that could enter clinical trials this year.
Price PointsThe takeout premium is less than 10%, which leads me to believe that perhaps the parties involved in the negotiations realized the stock was fully valued. Biotech acquisitions have sported some large premiums over the past few months, including the 100% premium Merck (MRK) paid for Sirna Therapeutics last year. Genentech (DNA) is in the process of acquiring Tanox (TNOX), for which it will pay a 47% premium.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV